Abstract
Allyl difluorides are pervasive in the pharmaceutical arena, but synthetic challenges in the construction of highly substituted derivatives impede chemical space exploration. Consequently, efforts to develop general approaches that display high levels of regio‐ and stereo‐selectivity continue to be intensively pursued. To contribute to this vibrant area of contemporary organofluorine chemistry, a highly efficient difluorinative rearrangement of densely substituted cyclopropenes is disclosed under the auspices of I(I)/I(III) catalysis. This platform leverages a highly intuitive ring opening model that enables di‐, tri‐, and tetra‐substituted allyl difluorides to be generated with high levels of stereoselectivity where the transient I(III) center serves as a traceless directing group. X‐ray crystal structural analysis is described together with facile post‐reaction modifications that include expedient access to fluorinated indenes. Given the ubiquity of the allyl difluoride chemotype in drug discovery, it is envisaged that this operationally simple, organocatalytic platform will expedite bioisostere design.
Keywords: Allylic compounds, Fluorination, Hypervalent iodine, Organocatalysis, Stereoselectivity
A difluorinative rearrangement of substituted cyclopropenes is disclosed using I(I)/I(III) catalysis. This platform enables di‐, tri‐, and tetra‐substituted allyl difluorides to be generated with high levels of stereoselectivity, with the I(III) center serving as a traceless directing group. X‐ray crystal structural analysis is described together with facile post‐reaction modifications that include expedient access to fluorinated indenes.
![]()
Introduction
Molecular editing with fluorine is a core objective in contemporary synthetic research, and an endeavour that continues to be highly disruptive in the quest for innovative functional small molecules with societal relevance.[ 1 , 2 , 3 , 4 , 5 , 6 , 7 ] Born out of necessity, the contemporary fluorination arsenal reflects an ever‐expanding reliance on fluorinated pharmaceuticals[ 8 , 9 , 10 , 11 , 12 ] and agrochemicals,[ 13 , 14 , 15 ] juxtaposed with the paucity of naturally occurring fluorinated building blocks to expedite synthesis.[ 16 ] The field remains an exemplar of how chemical intuition has been brought to bear in the creation of small molecules with conformational and physicochemical profiles that can be predicated a priori,[ 17 , 18 ] and which have no biological blueprints. Of the plenum of innovative fluorinated motifs in existing chemical space, allyl difluorides have become ubiquitous in medicinal chemistry and chemical biology on account of the subtle changes associated with CH2 to CF2 isosteric replacement (Figure 1a).[ 19 , 20 , 21 , 22 ] Pertinent structural features include a expanded internal FCF angle (cf. HCH) on account of fluorine–fluorine electrostatic repulsion,[ 23 , 24 , 25 , 26 ] and well‐defined exit vectors that allow for subsequent derivatisation. In addition, CH2 to CF2 substitution is accompanied by localized partial charge inversion,[ 27 ] rendering allyl difluorides powerful (bio)isosteres of a range of common chemotypes that include α,β‐unsaturated carbonyl compounds, their hydrates, enol ethers, and alkenes (Figure 1a , left).[ 28 , 29 ] Consequently, efforts to facilitate synthesis have been intensively pursued. Despite this, the regio‐ and stereo‐controlled synthesis of allyl difluorides remains challenging, with sterically congested systems proving to be particularly intractable.[ 30 ] Of the plenum of existing methods to enable the synthesis of allyl difluoride motifs, coupling reactions of alkenes or alkynes with difluoromethyene (CF2)‐containing reagents are frequently leveraged. Predicated on C(sp3)–C(sp2) bond formation, these approaches are valuable entry points to generate fluorinated products with electron‐withdrawing groups attached to the fluorine‐bearing carbon (Figure 1b).[ 31 , 32 , 33 , 34 , 35 , 36 , 37 ] Similarly, the generation of gem‐difluoroallylated arenes by gem‐difluoroallylation again allow carbon–carbon bond forming events to be harnessed.[ 38 , 39 , 40 , 41 , 42 , 43 ] However, the synthesis of the corresponding gem‐difluoroallylated alkanes remains challenging: the coupling of conventional reagents (e.g., 3‐bromo‐3,3‐difluoropropene) with aliphatic nucleophiles is complicated by formation of regioisomeric gem‐difluoroalkenes.[ 44 , 45 ] Innovations in reagent design have partially alleviate this challenge, but success has been limited to the generation of terminal alkenes products.[ 46 , 47 , 48 ] To the best of our knowledge, only a single case in which the formation of a gem‐difluoroallylated alkane containing a di‐substituted internal alkene as a Z/E mixture has been reported using an alkyl‐substituted sulfonium salt.[ 48 ] Importantly, sulfide‐catalyzed fluorinative Meyer–Schuster‐like rearrangements of propargylic fluorides and rhodium(III)‐catalyzed hydroarylation of α,α‐difluoromethylene alkynes have proven effective in the synthesis of tri‐substituted gem‐difluoroallylated alkanes.[ 49 , 50 ] Nevertheless, general platforms to expedite the synthesis of gem‐difluoroallylated arenes and alkanes with high stereoselectivity remains conspicuously underrepresented.
Figure 1.

Motivation and conceptual framework for the study. a) Bioisostere design and selected examples of bioactive small molecules. b) Synthesis routes to allyl difluorides based on transition metal catalysis. c) Reaction blueprint to enable the regio‐ and stereoselective difluorinative rearrangement of cyclopropenes based on I(I)/I(III) catalysis. d) The Rh‐catalyzed carbyne transfer approach to allyl fluorides by Suero and co‐workers.
To augment the existing method portfolio, and enable the construction of highly substituted allyl difluorides, a conceptually orthogonal approach was envisaged in which the substituents would be pre‐installed in an easily accessible cyclopropene fragment (Figure 1c).
It was envisaged that a main group I(I)/I(III) catalysis fluorination platform[ 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ] would be ideally suited to activate the π‐bond toward an initial nucleophilic fluorination through in situ generation of an ArIF2 species.[ 79 , 80 , 81 ] The constraints imposed by the rigid, highly substituted cyclopropene would enforce a 1,2‐anti relationship of the fluorine and hypervalent iodine substituents following the initial addition. Moreover, the regio‐selectivity of the process, which could lead to two conceivable isomeric anti‐adducts, would be dictated by the disparity of the alkene positions and stabilizing interactions (e.g., ArI+F cation‐π)[ 1 , 2 ] imparted by the substituents at the C(sp3) position of the cyclopropene. Addition of the second fluoride nucleophile to the cyclopropyl intermediate (I) is anticipated to occur at the more electrophilic fluorine‐bearing carbon, thereby delivering the geminal difluoro motif and liberating the catalyst. Confidence in this approach via intermediate I stemmed from the seminal work by Fleming and Thomas on the stereochemical course of halocyclopropane ring‐opening.[ 82 , 83 , 84 , 85 , 86 ] In addition to this asynchronous, concerted model, the leaving group ability of I(III) renders the involvement of an allyl cation intermediate (II) plausible. At this end of the mechanistic spectrum, the ability of fluorine to act as a cation stabilizing auxiliary[ 87 ] enables the the regioselectivity of the second C(sp3)–F bond forming event to be rationalized. Importantly, Suero and co‐workers have reported an elegant Rh‐catalyzed carbyne transfer approach to allyl fluorides in which intermediates III and IV are implicated (Figure 1d).[ 88 , 89 ] This approach leverages a diazo‐containing iodonium reagent to process 1,1‐disubstituted alkenes to the branched products through the action of a Rh2(esp)2. Although caution must be exercised when drawing mechanistic comparisons on account of the very different conditions involved, the studies by Fleming and Thomas[ 82 , 83 , 84 , 85 , 86 ] and Suero and colleagues[ 88 , 89 ] are instructive when contemplating the mechanistic continuum. Collectively, the blueprint shown in Figure 1c shifts stereoselective allyl difluoride synthesis away from (often fluorinated) linear precursors and enables key events to be regulated in a highly‐preorganized environment.
Results and Discussion
To explore the feasibility of an I(I)/I(III) catalysis platform, the trisubstituted cyclopropene S1 was selected as a model substrate for reaction development. Initial reactions were performed with p‐TolI (20 mol%), Selectfluor (1.5 equiv.) as an oxidant, and methylene chloride (DCM) as the reaction medium. Variation of the amine:HF ratio (entries 1–3) revealed 1:7 to be optimal and this served as the choice for the reminder of the investigation (Figure 2). A solvent screen (entries 4 and 5) identified ethyl trifluoroacetate (ETFA) as being the most effective reaction medium for the title transformation. Comparison of aryl‐iodide organocatalysts C1–C7 (entries 6–11) confirmed C7 to be the most efficient catalyst, furnishing the desired allyl difluoride 1 in 83% yield. It is important to note that the reaction proved to be highly stereoselective (>20:1), and no competing vicinal difluorination was observed.[ 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ] Replacing Selectfluor with m‐CPBA proved to be detrimental to efficiency (entry 12), and reducing the catalyst loading led to a slight decrease in yield (entry 13). Control experiments without the catalyst (entry 14) and the terminal oxidant (entry 15) inhibited the reaction, which support the involvement of an I(I)/I(III) catalysis cycle (Figure 2a).
Figure 2.

Reaction development. a) Optimization of reaction conditions. Standard reaction conditions: cyclopropene S1 (0.10 mmol), catalyst (20 mol%), amine•HF (0.25 mL), solvent (0.25 mL), and oxidant (0.15 mmol). Ethyl fluoroacetate was used as internal standard. Conversions and yields were determined by 19F NMR. The stereoselectivity was >20:1 in all cases. b) Influence of the amine:HF ratio on the transformation. Standard reaction conditions: cyclopropene S1 (0.10 mmol), C1 (20 mol%), amine•HF (0.25 mL), DCM (0.25 mL), and Selectfluor (0.15 mmol). c) 19F‐1H HOE analysis of the product E‐1. a)10 mol% of catalyst was used.
To correlate the Brønsted acidity with reaction efficiency,[ 71 , 90 , 91 ] the amine:HF ratio was plotted against yield as determined by 19F NMR spectroscopy.
The plateau observed with the 1:7 amine:HF ratio is evident from Figure 2b: this sensitivity is consistent with early observations on the activation of iodobenzene dichloride catalysed by trifluoroacetic acid.[ 92 , 93 , 94 ] In addition to securing the configuration of product E‐1 by HOE analysis (Figure 2c), it was possible to unequivocally establish the molecular connectivity by single crystal X‐ray diffraction analysis (vide infra).
With optimized conditions for the difluorinative rearrangement of cyclopropenes having been identified, the scope and limitations of the transformation were explored (Figure 3). As previously noted, subtle variations in the amine:HF ratio were found to fine‐tune reaction performance in individual cases. Initially, the impact of modifying the C(sp3) position was investigated (Figure 3, highlighted in green).
Figure 3.

Scope for the stereoselective difluorination to access trisubstituted alkenes. Reaction conditions: cyclopropene (0.10 mmol), catalyst (20 mol%), amine•HF (0.25 mL), ETFA (0.25 mL), and Selectfluor (0.15 mmol). Isolated yields are given. The stereoselectivity was determined by 19F NMR from the crude reaction mixture. a)Amine:HF = 1:9.2. b)Amine:HF = 1:8.5. c)Amine:HF = 1:8.0. d)Amine:HF = 1:7.5. e)Amine:HF = 1:7.0. f)Amine:HF = 1:6.5. g)Amine:HF = 1:5.5. h)Amine:HF = 1:5.0.i)Amine:HF = 1:4.5. j)Reaction performed on 0.20 mmol scale. k)Reaction performed on 0.05 mmol scale. l)DCM was used as solvent. m) C1 was used as catalyst. n) C2 was used as catalyst.
The introduction of halogens, electron‐withdrawing groups and short alkyl fragments on the aryl ring proved unproblematic, and the target trisubstituted allylic difluorides were forged with high levels of stereoselectivity (1–5, >20:1). Replacing the aryl substituent with a benzyl group was also tolerated (6), albeit with a reduction in selectivity: this supports the notion that the aryl substituent biases alkene geometry, potentially through a stabilizing interaction in the initial anti‐addition step (e.g., ArI+F cation‐π).[ 1 , 2 ] Regrettably, efforts to replace the CF3 unit with small alkyl groups was unsuccessful. To further establish generality of substrate scope, subsequent modifications were performed at the alkene unit of the cyclopropene (shown in gray). To that end, a range of cyclopropenes with aryl substituents were initially subjected to the general catalysis conditions and this led to the formation of the chlorine derivative (7), ester (8) and nitrile (9). Simple alkyl and cycloalkyl derivatives were also compatible with the reaction conditions (10 and 11), and the transformation proved to be highly chemoselective for the cyclopropene motif: competing 1,3‐difluorination of the cyclopropane was not observed (12). Gratifyingly, the trifluoromethyl derivatives 13 and 14, the nitro derivative 15 and bromide 16 were generated and which contain Michael acceptor motifs. Variation of the ester moiety (17) and replacement with a methyl group, to furnish 18 and 19 respectively, occurred in a highly stereoselective fashion (>20:1).
An interesting observation resulted from the replacement of the ester group with a phenyl substituent (13 versus 20 and 21). Interestingly, this led to the predominant formation of the Z‐isomer in the case of 20. It is likely that the directing influence of the ester[ 95 ] complicates with the model described in Figure 1. Interestingly, exploring the influence of aryl to alkyl exchange at the neighbouring position (in gray) results in preferential formation of the E‐isomer 21. (N.B. In the starting cyclopropene, the only variation is the aryl / alkyl substitution S20 and S21 in the Supporting Information). Finally, the compatibility of the method with a dihydrocholesterol derivative was validated and enabled compound 22 to be generated stereoselectively (>20:1).
The allylic difluoride 3 was crystalline and it was possible to grow crystals that were suitable for X‐ray analysis (Figure 4).[ 96 ] It is interesting to note that a small difference in bond lengths was observed between the two allylic C─F bonds (1.3599 Å versus 1.3846 Å): this can be rationalized by invoking a stabilizing hyperconjugative π→σ*C─F interaction between the alkene π‐bond and the C(sp3)─F antibonding orbital which is coplanar.[ 1 , 97 ] A second intriguing feature of this analysis proved to be the short distance between one of the F atoms (F4) and the C(sp2) center of the neighbouring ipso‐carbon of the aryl ring. The distance F4…C11 is 2.7862 Å, which is less than the sum of the van der Waals distance (3.17 Å).[ 98 , 99 ] It is interesting to note that the F4 fluorine atom is slightly bent out from the plane of π system (torsion angle C2─C3─C4─F4 is 23.2°), thereby enabling this proximity to the ipso‐C atom (C11).
Figure 4.

Crystal structure analysis of allylic difluoride 3. Thermal ellipsoids are shown at 50% probability.
Having established a stereoselective difluorination platform that enables the operationally simple generation of trisubstituted alkenes, attention was then turned to expanding the scope of the process to encompass di‐, and tetrasubstitution (Figure 5). This was possible but required a reassessment of the reaction conditions, such that dichloromethane was used as the solvent instead of ethyl trifluoroacetate and a short process of catalyst refinement was conducted. For the construction of disubstituted alkenes, a general trend was noted: whilst catalyst PhI (C2) is a highly competent catalyst, the resorcinol derivative (C7) proved to be more stereoselective. Exposing simple alkyl derivatives to the catalysis conditions delivered the expected disubstituted alkene 23 with good level of stereoselectivity (up to 14:1 Z:E). Gratifyingly, unprotected alcohols (24) and medicinally relevant pyridines (25) were also compatible with the reaction conditions.
Figure 5.

Scope for the stereoselective difluorination to access di‐ and tetra‐substituted alkenes. Reaction conditions: cyclopropene (0.10 mmol), catalyst (20 mol%), amine•HF (0.25 mL), DCM (0.25 mL), and Selectfluor (0.15 mmol). Isolated yields were given. The stereoselectivity was determined by 19F NMR from the crude reaction mixture. a)Amine:HF = 1:6.0. b)Amine:HF = 1:5.5. c)Amine:HF = 1:4.5. d)19F NMR yield using ethyl fluoroacetate as internal standard.
For the construction of the more challenging tetrasubstituted alkenes, the revised conditions once again enabled the target allyl difluoride 26 to be generated. The positive impact of the electron‐withdrawing aryl substituent was fully leveraged by installing a trifluoromethyl handle, thereby facilitating access to 27. Amide groups were tolerated (28). Notably, this approach also enabled the cyclic alkene 29 to be prepared with synthetically useful levels of efficiency. Collectively, examples 23–25 illustrate the value of this approach in accessing rare, Z‐configured products (up to Z:E 14:1), whereas compounds 26–29 illustrate the insensitivity of the method to sterically demanding substrates (up to 69% yield).
To further demonstrate the synthetic utility of this difluorinative rearrangement of cyclopropenes, a series of product derivatization reactions were conducted (Figure 6). Initially, alkene 1 was converted to the vicinal diol 30 through treatment with OsO4 / NMO. Under hydrodefluorination conditions, the trifluoromethylated alkene 1 could be smoothly processed to the terminal monofluoroalkene 31.[ 100 ] Epoxidation of alkene 13 proved facile in the presence of m‐CPBA, furnishing 32 in 90% yield.[ 101 ] Moreover, the homoallyl alcohol 33 was generated via reduction of 18 and subsequent hydrodefluorination of the intermediate allyl alcohol. Hydrogenation of alkene 13 enabled alkane 34 to be prepared, and cyclopropanation of alkene 13 allowed the α,α‐difluorocyclopropane 35 to be synthesized.
Figure 6.

Product derivatisation. Conditions: a) OsO4, NMO, THF, H2O, 50 °C−65 °C. b) LiAlH4, THF, rt. c) m‐CPBA, KOH, DCM, rt. d) DIBAL‐H, THF, ‐78 °C ‐ rt. e) Pd/C, H2, MeOH, rt. f) trimethylsulfoxonium iodide, NaH, DMSO, rt.
Leveraging the intrinsic acidity of (HF‐based) catalysis conditions in multi‐step processes has attracted attention in recent years.[ 66 , 102 ] Motivated by the prominence of indenes in pharmaceuticals (Figure 7a),[ 103 , 104 ] it was envisaged that a one‐pot sequence could provide enabling access to fluorinated isosteres: this approach would combine the title transformation with a Brønsted acid activation event to enable facile conversion of cyclopropenes to fluorinated indenes (Figure 7b). Specifically, the transformation would be reliant on the in situ generation of an allyl difluoride under the auspices of I(I)/I(III) catalysis. Inspired by the work of Paquin[ 105 ] and previous work from this laboratory[ 66 ] on the activation of benzylic C─F bonds, it was conceived that a Friedel–Crafts‐type cyclization would liberate a fluorinated indene under the Brønsted acidic reaction conditions. To validate the working hypothesis, fully substituted cyclopropene S36 was prepared and exposed to catalysis condition using aryl iodide C7, Selectfluor and HF source. Gratifyingly, this enabled the desired fluorinated indene 36 to be generated in 55% yield (Figure 7c). Variations of the allyl and alkenyl substituents were also tolerated (37 and 38), providing further validation of the synthetic versatility of products generated by this I(I)/I(III)‐catalysis‐based difluorinative rearrangement of cyclopropenes.
Figure 7.

Ring expanding fluorination of cyclopropenes. a) Selected examples of bioactive small molecules containing the indene unit. b) Integrating an I(I)/I(III) catalysis event in a one‐pot approach for the synthesis of fluorinated indenes from cyclopropenes. c) Scope of the title transformation. Standard reaction conditions: cyclopropene (0.10 mmol), C7 (20 mol%), amine•HF (0.25 mL), DCM (0.25 mL), and Selectfluor (0.15 mmol). Isolated yields were given. a)Amine:HF = 1:9.2. b)Amine:HF = 1:8.5. c)Amine:HF = 1:7.0.
Conclusions
Motivated by the prominence and versatility of allyl difluorides, and the conspicuous dearth of general methods to facilitate their construction, a highly regio‐ and stereoselective difluorinative rearrangement of cyclopropenes has been developed leveraging a metal‐free (I)/I(III) catalysis platform. Based on a stereochemical model that exploits the transient iodine (III) substituent as a traceless steering element, the method enables the formation of di‐, tri‐, and tetrasubstituted gem‐difluoroallylated arenes and alkanes with broad functional group tolerance. High levels of stereocontrol are observed (up to 20:1), and X‐ray analysis reveals the subtle impact of the π‐system on proximal C─F bond lengths. The synthetic utility of the transformation is showcased through facile product derivatization. Moreover, given the importance of indenes in bioactive small molecules, integrating this process in a reaction cascade is validated, thereby enabling the synthesis of fluorinated indenes from cyclopropenes in a single operation. It is envisaged that this platform to enable the stereocontrolled synthesis of heavily substituted allyl difluorides will expedite organofluorine chemical space exploration.[ 106 ]
Conflict of Interests
The authors declare no conflict of interest.
Supporting information
Supporting Information
Acknowledgements
The authors acknowledge generous financial support from the University of Münster and the Alexander von Humboldt Foundation (fellowship to Z.X.W).
Open access funding enabled and organized by Projekt DEAL.
Dedicated to Professor Steven V. Ley FRS on the occasion of his 80th birthday
Wang Zi‐X., Heckmann N. A., Daniliuc C. G., Gilmour R., Angew. Chem. Int. Ed. 2025, 64, e202518520. 10.1002/anie.202518520
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Zimmer L. E., Sparr C., Gilmour R., Angew. Chem. Int. Ed. 2011, 50, 11860–11871. [DOI] [PubMed] [Google Scholar]
- 2. Aufiero M., Gilmour R., Acc. Chem. Res. 2018, 51, 1701–1710, 10.1021/acs.accounts.8b00192. [DOI] [PubMed] [Google Scholar]
- 3. Liang T., Neumann C. N., Ritter T., Angew. Chem. Int. Ed. 2013, 52, 8214–8264, 10.1002/anie.201206566. [DOI] [PubMed] [Google Scholar]
- 4. Wang M., Ruskin J., Marques J., Garrison N. G., Lectka T., Chem. Rev. 2025, 10.1021/acs.chemrev.5c00363. [DOI] [PubMed] [Google Scholar]
- 5. Kalita S. J., Qi J., Saha D.,Huang Y.‐Y., Shibata N., Chem. Rev. 2025, 125, 8477–8654, 10.1021/acs.chemrev.5c00177. [DOI] [PubMed] [Google Scholar]
- 6. Woge F., Wang M., White B., Kiame N., Siegler M. A., Dudding T., Pitts C. R., Lectka T., J. Org. Chem. 2025, 90, 9046–9052, 10.1021/acs.joc.5c00819. [DOI] [PubMed] [Google Scholar]
- 7. Ruskin J., Dekeyser R., Garrison N. G., Williams P., Kramer‐Johansen M., Majumdar A., Dudding T., Huczyński A., Lectka T., Chem. Sci. 2025, 16, 8729–8734, 10.1039/D5SC01857A. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Müller K., Faeh C., Diederich F., Science 2007, 317, 1881–1886. [DOI] [PubMed] [Google Scholar]
- 9. Purser S., Moore P. R., Swallow S., Gouverneur V., Chem. Soc. Rev. 2008, 37, 320–330, 10.1039/B610213C. [DOI] [PubMed] [Google Scholar]
- 10. Meanwell N. A., J. Med. Chem. 2011, 54, 2529–2591, 10.1021/jm1013693. [DOI] [PubMed] [Google Scholar]
- 11. Gillis E. P., Eastman K. J., Hill M. D., Donnelly D. J., Meanwell N. A., J. Med. Chem. 2015, 58, 8315–8359, 10.1021/acs.jmedchem.5b00258. [DOI] [PubMed] [Google Scholar]
- 12. Han J., Remete A. M., Dobson L. S., Kiss L., Izawa K., Moriwaki H., Soloshonok V. A., O´Hagan D., J. Fluorine Chem. 2020, 239, 109639, 10.1016/j.jfluchem.2020.109639. [DOI] [Google Scholar]
- 13. Fujiwara T., O'Hagan D., J. Fluorine Chem. 2014, 167, 16–29, 10.1016/j.jfluchem.2014.06.014. [DOI] [Google Scholar]
- 14. Qacemi M. E., Rendine S., Mainfisch P., Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals, Elsevier Inc, London: 2019, pp. 607–623. [Google Scholar]
- 15. Ogata Y., Tokunaga E., Kobayashi O., Hirai K., Shibata N., iScience 2020, 23, 101467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. O'Hagan D., Schaffrath C., Cobb S. L., Hamilton J. T. G., Murphy C. D., Nature 2002, 416, 279–279, 10.1038/416279a. [DOI] [PubMed] [Google Scholar]
- 17. O´Hagan D., Chem.‐Eur. J. 2020, 26, 7981–7997, 10.1002/chem.202000178. [DOI] [PubMed] [Google Scholar]
- 18. Mondal R., Agbaria M., Nairoukh Z., Chem.‐Eur. J. 2021, 27, 7193–7213. [DOI] [PubMed] [Google Scholar]
- 19. Sun W. C., Ng C. S., Prestwich G. D., J. Org. Chem. 1992, 57, 132–137, 10.1021/jo00027a025. [DOI] [Google Scholar]
- 20. Saphir S., Katalan S., Yacov G., Berliner A., Redy‐Keisar O., Fridkin G., Ghindes‐Azaria L., Columbus I., Pevzner A., Drug E., Prihed H., Gershonov E., Eichen Y., Elias S., Parvari G., Zafrani Y., Chem.‐Eur. J. 2023, 29, e202202939, 10.1002/chem.202202939. [DOI] [PubMed] [Google Scholar]
- 21. Holovach S., Melnykov K. P., Skreminskiy A., Herasymchuk M.,Tavlui O., Aloshyn D., Borysko P., Rozhenko A. B., Ryabukhin S. V., Volochnyuk D. M., Grygorenko O. O., Chem.‐Eur. J. 2022, 28, e202200331, 10.1002/chem.202200331. [DOI] [PubMed] [Google Scholar]
- 22. Uno H., Kawai K., Shiro M., Shibata N., ACS Catal. 2020, 10, 14117–14126, 10.1021/acscatal.0c03927. [DOI] [Google Scholar]
- 23. O´Hagan D., Wang Y., Skibinski M., Slawin A. M. Z., Pure Appl. Chem. 2012, 84, 1587–1595, 10.1351/PAC-CON-11-09-26. [DOI] [Google Scholar]
- 24. Corr M. J., Cormanich R. A., von Hahmann C. N., Cordes D. B., Slawin A. M. Z., O´Hagan D., Org. Biomol. Chem. 2016, 14, 211–219, 10.1039/C5OB02023A. [DOI] [PubMed] [Google Scholar]
- 25. Häfliger J., Livingstone K., Daniliuc C. G., Gilmour R., Chem. Sci. 2021, 12, 6148–6152, 10.1039/D1SC01132D. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Neufeld J., Stünkel T., Mück‐Lichtenfeld C., Daniliuc C. G., Gilmour R., Angew. Chem. Int. Ed. 2021, 60, 13647–13651, 10.1002/anie.202102222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. O'Hagan D., Chem. Soc. Rev. 2008, 37, 308–319, 10.1039/B711844A. [DOI] [PubMed] [Google Scholar]
- 28. Erickson J. A., McLoughlin J. I., J. Org. Chem. 1995, 60, 1626–1631, 10.1021/jo00111a021. [DOI] [Google Scholar]
- 29. Sessler C. D., Rahm M., Becker S., Goldberg J. M., Wang F., Lippard S. J., J. Am. Chem. Soc. 2017, 139, 9325–9332, 10.1021/jacs.7b04457. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Tomon D., Arimitsu S., Eur. J. Org. Chem. 2025, 28, e202401162. [Google Scholar]
- 31.For selected examples see: Xu T., Cheung C. W., Hu X., Angew. Chem. Int. Ed. 2014, 53, 4910–4914, 10.1002/anie.201402511. [DOI] [PubMed] [Google Scholar]
- 32. Feng Z., Min Q.‐Q., Zhao H.‐Y., Gu J.‐W., Zhang X., Angew. Chem. Int. Ed. 2015, 54, 1270–1274, 10.1002/anie.201409617. [DOI] [PubMed] [Google Scholar]
- 33. Ivanova M. V., Bayle A., Besset T., Poisson T., Pannecoucke X., Angew. Chem. Int. Ed. 2015, 54, 13406–13410, 10.1002/anie.201507130. [DOI] [PubMed] [Google Scholar]
- 34. Li Z., García‐Domínguez A., Nevado C., J. Am. Chem. Soc. 2015, 137, 11610–11613, 10.1021/jacs.5b07432. [DOI] [PubMed] [Google Scholar]
- 35. Li G., Wang T., Fei F., Su Y.‐M., Li Y., Lan Q., Wang X.‐S., Angew. Chem. Int. Ed. 2016, 55, 3491–3495, 10.1002/anie.201511321. [DOI] [PubMed] [Google Scholar]
- 36. Wei X.‐J., Boon W., Hessel V., Noël T., ACS Catal. 2017, 7, 7136–7140, 10.1021/acscatal.7b03019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Wang S., Zhang J., Kong L., Tan Z., Bai Y., Zhu G., Org. Lett. 2018, 20, 5631–5635, 10.1021/acs.orglett.8b02336. [DOI] [PubMed] [Google Scholar]
- 38.For selected examples see: Min Q.‐Q., Yin Z., Feng Z., Guo W.‐H., Zhang X., J. Am. Chem. Soc. 2014, 136, 1230–1233, 10.1021/ja4114825. [DOI] [PubMed] [Google Scholar]
- 39. Lou Y.‐G., Wang A.‐J., Zhao L., He L.‐F., Li X.‐F., He C.‐Y., Zhang X., Chem. Commun. 2019, 55, 3705–3708, 10.1039/C8CC10212K. [DOI] [PubMed] [Google Scholar]
- 40. Tang L., Liu Z.‐Y., She W., Feng C., Chem. Sci. 2019, 10, 8701–8705, 10.1039/C9SC01966A. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Sakamoto S., Butcher T. W., Yang J. L., Hartwig J. F., Angew. Chem. Int. Ed. 2021, 60, 25746–25752, 10.1002/anie.202111476. [DOI] [PubMed] [Google Scholar]
- 42. Zhang B., Zhang X., Chem. Commun. 2016, 52, 1238–1241, 10.1039/C5CC08394J. [DOI] [PubMed] [Google Scholar]
- 43. Shi C.‐Y., Chen X.‐Q., Zeng R., Lu H., Fan Z., Zhang A., Org. Lett. 2023, 25, 3870–3875, 10.1021/acs.orglett.3c00873. [DOI] [PubMed] [Google Scholar]
- 44. Tellier F., Baudry M., Sauvêtre R., Tetrahedron Lett. 1997, 38, 5989–5992, 10.1016/S0040-4039(97)01363-4. [DOI] [Google Scholar]
- 45. Kirihara M., Takuwa T., Okumura M., Wakikawa T., Takahata H., Momose T., Takeuchi Y., Nemoto H., Chem. Pharm. Bull. 2000, 48, 885–888, 10.1248/cpb.48.885. [DOI] [PubMed] [Google Scholar]
- 46. Gao X., Ren X., Deng W., Zhang X., Chin. J. Chem. 2023, 41, 3521–3527, 10.1002/cjoc.202300436. [DOI] [Google Scholar]
- 47. Feng X.‐T., Min Q.‐Q., Zeng X., Zhao H.‐Y., Zhang X., ACS Catal. 2024, 14, 5879–5887, 10.1021/acscatal.4c00281. [DOI] [Google Scholar]
- 48. Feng X.‐T., Ren J.‐X., Gao X., Min Q.‐Q., Zhang X., Angew. Chem. Int. Ed. 2022, 61, e202210103, 10.1002/anie.202210103. [DOI] [PubMed] [Google Scholar]
- 49. Liao L., An R., Li H., Xu Y., Wu J.‐J., Zhao X., Angew. Chem. Int. Ed. 2020, 59, 11010–11019, 10.1002/anie.202003897. [DOI] [PubMed] [Google Scholar]
- 50. Wang C.‐Q., Zhang Y., Feng C., Angew. Chem. Int. Ed. 2017, 56, 14918–14922, 10.1002/anie.201708505. [DOI] [PubMed] [Google Scholar]
- 51.For selected discussions on I(III)‐catalysed fluorination see: Cresswell A. J., Eey S. T.‐C., Denmark S. E., Angew. Chem. Int. Ed. 2015, 54, 15642–15682, 10.1002/anie.201507152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Kohlhepp S. V., Gulder T., Chem. Soc. Rev. 2016, 45, 6270–6288. [DOI] [PubMed] [Google Scholar]
- 53. Arnold A. M., Ulmer A., Gulder T., Chem.‐Eur. J. 2016, 22, 8728–8739, 10.1002/chem.201600449. [DOI] [PubMed] [Google Scholar]
- 54. Molnár I. G., Thiehoff C., Holland M. C., Gilmour R., ACS Catal. 2016, 6, 7167–7173, 10.1021/acscatal.6b02155. [DOI] [Google Scholar]
- 55.For selected examples of 1,1‐difluorination, see: Hara S., Nakahigashi J., Ishi‐I K., Fukuhura T., Yoneda N., Tetrahedron Lett. 1998, 39, 2589–2592, 10.1016/S0040-4039(98)00276-7. [DOI] [Google Scholar]
- 56. Ilchenko N. O., Tasch B. O. A., Szabó K. J., Angew. Chem. 53, 13111–13115. [DOI] [PMC free article] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2014, 53, 12897–12901, 10.1002/anie.201408812. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Kitamura T., Muta K., Oyamada J., J. Org. Chem. 2015, 80, 10431–10436, 10.1021/acs.joc.5b01929. [DOI] [PubMed] [Google Scholar]
- 58. Banik S. M., Medley J. W., Jacobsen E. N., Science 2016, 353, 51–54, 10.1126/science.aaf8078. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Ilchenko N. O., Szabó K. J., J. Fluorine Chem. 2017, 203, 104–109, 10.1016/j.jfluchem.2017.07.006. [DOI] [Google Scholar]
- 60. Scheidt F., Neufeld J., Schäfer M., Thiehoff C., Gilmour R., Org. Lett. 2018, 20, 8073–8076, 10.1021/acs.orglett.8b03794. [DOI] [PubMed] [Google Scholar]
- 61. Zhao Z., Racicot L., Murphy G. K., Angew. Chem. 56, 11778–11781. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2017, 56, 11620–11623, 10.1002/anie.201706798. [DOI] [PubMed] [Google Scholar]
- 62. Kitamura T., Yoshida K., Mizuno S., Miyake A., Oyamada J., J. Org. Chem. 2018, 83, 14853–14860, 10.1021/acs.joc.8b02473. [DOI] [PubMed] [Google Scholar]
- 63. Lv W.‐X., Li Q., Li J.‐L., Li Z., Lin E., Tan D.‐H., Cai Y.‐H., Fan W.‐X., Wang H., H. Angew. Chem. 2018, 57, 16782–16786. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2018, 57, 16544–16548, 10.1002/anie.201810204. [DOI] [PubMed] [Google Scholar]
- 64. Zhao Z., To A. J., Murphy G. K., Chem. Commun. 2019, 55, 14821–14824, 10.1039/C9CC08310C. [DOI] [PubMed] [Google Scholar]
- 65. Meyer S., Göbel L., Livingstone K., Roblick C., Daniliuc C. G., Gilmour R., Tetrahedron 2022, 126, 132925, 10.1016/j.tet.2022.132925. [DOI] [Google Scholar]
- 66. Häfliger J., Ruyet L., Stübke N., Daniliuc C. G., Gilmour R., Nat. Commun. 2023, 14, 3207, 10.1038/s41467-023-38957-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Wang Z.‐X., Livingstone K., Hümpel C., Daniliuc C. G., Mück‐Lichtenfeld C., Gilmour R., Nat. Chem. 2023, 15, 1515–1522, 10.1038/s41557-023-01344-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Ruyet L., Roblick C., Häfliger J., Wang Z.‐X., Stoffels T. J., Daniliuc C. G., Gilmour R., Angew. Chem. Int. Ed. 2024, 63, e202403957. [DOI] [PubMed] [Google Scholar]
- 69.For selected examples of 1,2‐difluorination see: Banik S. M., Medley J. W., Jacobsen E. N., J. Am. Chem. Soc. 2016, 138, 5000–5003, 10.1021/jacs.6b02391. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Molnár I. G., Gilmour R., J. Am. Chem. Soc. 2016, 138, 5004–5007, 10.1021/jacs.6b01183. [DOI] [PubMed] [Google Scholar]
- 71. Scheidt F., Schäfer M., Sarie J. C., Daniliuc C. G., Molloy J. J., Gilmour R., Angew. Chem. Int. Ed. 2018, 57, 16431–16435, 10.1002/anie.201810328. [DOI] [PubMed] [Google Scholar]
- 72. Erdeljac N., Kehr G., Ahlqvist M., Knerr L., Gilmour R., Chem. Commun. 2018, 54, 12002–12005, 10.1039/C8CC05643A. [DOI] [PubMed] [Google Scholar]
- 73. Erdeljac N., Bussmann K., Schöler A., Hansen F. K., Gilmour R., ACS Med. Chem. Lett. 2019, 10, 1336–1340, 10.1021/acsmedchemlett.9b00287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Haj M. K., Banik S. M., Jacobsen E. N., Org. Lett. 2019, 21, 4919–4923, 10.1021/acs.orglett.9b00938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75. Erdeljac N., Thiehoff C., Jumde R., Daniliuc C., Hoeppner S., Faust A., Hirsch A. K. H., Gilmour R., J. Med. Chem. 2020, 63, 6225–6237, 10.1021/acs.jmedchem.0c00648. [DOI] [PubMed] [Google Scholar]
- 76. Doobary S., Sedikides A. T., Caldora H. P., Poole D. L., Lennox A. J. J., Angew. Chem. Int. Ed. 2020, 59, 1155–1160, 10.1002/anie.201912119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Meyer S., Häfliger J., Schäfer M., Molloy J. J., Daniliuc C. G., Gilmour R., Angew. Chem. Int. Ed. 2021, 60, 6430–6434, 10.1002/anie.202015946. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Martín‐Heras V., Daniliuc C. G., Gilmour R., Synthesis 2021, 53, 4203–4212. [Google Scholar]
- 79. Weinland R. F., Stille W., Chem. Ber. 1901, 34, 2631–2633, 10.1002/cber.190103402213. [DOI] [Google Scholar]
- 80. Ye C., Twamley B., Shreeve J. M., Org. Lett. 2005, 7, 3961–3964, 10.1021/ol051446t. [DOI] [PubMed] [Google Scholar]
- 81. Sarie J. C., Thiehoff C., Mudd R. J., Daniliuc C. G., Kehr G., Gilmour R., J. Org. Chem. 2017, 82, 11792–11798, 10.1021/acs.joc.7b01671. [DOI] [PubMed] [Google Scholar]
- 82. Fleming I., Thomas E. J., Tetrahedron Lett. 1972, 28, 4989–5001, 10.1016/0040-4020(72)88150-X. [DOI] [Google Scholar]
- 83. Moore W. R., Moser W. R., LaPrade J. E., J. Org. Chem. 1963, 28, 2200–2205, 10.1021/jo01044a012. [DOI] [Google Scholar]
- 84. Jefford C. W., Mahajan S., Waslyn J., Waegell B., J. Am. Chem. Soc. 1965, 87, 2183–2190, 10.1021/ja01088a016. [DOI] [Google Scholar]
- 85. DePuy C. H., Schnack L. G., Hausser J. W., J. Am. Chem. Soc. 1966, 88, 3343–3346, 10.1021/ja00966a029. [DOI] [Google Scholar]
- 86. DePuy C. H., Acc. Chem. Res. 1968, 1, 33–41, 10.1021/ar50002a001. [DOI] [Google Scholar]
- 87. Johnson W. S., Bartlett W. R., Czeskis B. A., Gautier A., Lee C. H., Lemoine R., Leopold E. J., Luedtke G., Bancroft K. J., J. Am. Chem. Soc. 1999, 64, 9587–9595. [Google Scholar]
- 88. Wang Z., Jiang L., Sarró P., Suero M. G., J. Am. Chem. Soc. 2019, 141, 15509–15514, 10.1021/jacs.9b08632. [DOI] [PubMed] [Google Scholar]
- 89. Jiang L., Sarró P., Teo W. J., Llop J., Suero M. G., Chem. Sci. 2022, 13, 4327–4333, 10.1039/D2SC00968D. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90. Longuet M., Vitse K., Martin‐Mingot A., Michelet B., Guégan F., Thibaudeau S., J. Am. Chem. Soc. 2024, 146, 12167–12173, 10.1021/jacs.4c02344. [DOI] [PubMed] [Google Scholar]
- 91. Sweeting S. G., Lennox A. J. J., J. Am. Chem. Soc. 2025, 147, 19329–19341, 10.1021/jacs.5c05472. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Cotter J., Andrews L., Keefer R., J. Am. Chem. Soc. 1962, 84, 793–797, 10.1021/ja00864a023. [DOI] [Google Scholar]
- 93. Sarie J. C., Neufeld J., Daniliuc C. G., Gilmour R., ACS Catal. 2019, 9, 7232–7237, 10.1021/acscatal.9b02313. [DOI] [Google Scholar]
- 94. Sarie J. C., Neufeld J., Daniliuc C. G., Gilmour R., Synthesis 2019, 51, 4408–4416. [Google Scholar]
- 95. Livingstone K., Siebold K., Meyer S., Martín‐Heras V., Daniliuc C. G., Gilmour R., ACS Catal. 2022, 12, 14507–14516, 10.1021/acscatal.2c04511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.CCDC number 2479575 contains the supplementary crystallographic data for 3. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.
- 97. Schaefer T., Schurko R. W., Sebastian R., Hruska F. E., Can. J. Chem. 1995, 73, 816–825, 10.1139/v95-102. [DOI] [Google Scholar]
- 98. Harry S. A., Kazim M., Nguyen P. M., Zhu A., Xiang M. R., Catazaro J., Siegler M., Lectka T., Angew. Chem. Int. Ed. 2022, 61, e202207966, 10.1002/anie.202207966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99. Stünkel T., Siebold K., Okumatsu D., Murata K., Ruyet L., Daniliuc C. G., Gilmour R., Chem. Sci. 2023, 14, 13574–13580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100. Poutrel P., Pannecoucke X., Jubault P., Poisson T., Org. Lett. 2020, 22, 4858–4863, 10.1021/acs.orglett.0c01701. [DOI] [PubMed] [Google Scholar]
- 101. García Ruano J., Fajardo C., Fraile A., Martín M. R., J. Org. Chem. 2005, 70, 4300–4306, 10.1021/jo050131o. [DOI] [PubMed] [Google Scholar]
- 102. Okoromoba O. E., Han J., Hammond G. B., Xu B., J. Am. Chem. Soc. 2014, 136, 14381–14384, 10.1021/ja508369z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103. Phillips A. J., Nasveschuk C. G., Henderson J. A., Liang Y., He M., Duplessis M., Chen C.‐L., WO2018/237026A1, 2018.
- 104. Bartlett M. J., Chin G. F., Clarke M. O., Cosman J. L., Ensan D., Goyal B., Ho S., Hui H. C., Mackman R. L., Mish M. R., Schroeder S. D., Shapiro N. D., Siegel D. S., Tang D. T., Yang H., US12110294B2, 2024.
- 105. Champagne P. A., Benhassine Y., Desroches J., Paquin J.‐F., Angew. Chem. Int. Ed. 2014, 53, 13835–13839, 10.1002/anie.201406088. [DOI] [PubMed] [Google Scholar]
- 106. Meyer S., Häfliger J., Gilmour R., Chem. Sci. 2021, 12, 10686–10695, 10.1039/D1SC02880D. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supporting Information
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
